Form 4: Flagship Pioneering Funds Acquire Pre-Funded Warrants in Foghorn Therapeutics Public Offering

Flagship Pioneering Special Opportunities Fund II and Flagship Pioneering Fund VII acquired pre-funded warrants to purchase Foghorn Therapeutics common stock in a recent public offering.

Summary

• On May 22, 2024, Flagship Pioneering Special Opportunities Fund II, L.P. and Flagship Pioneering Fund VII, L.P. acquired pre-funded warrants to purchase 1,814,914 and 1,814,915 shares of Foghorn Therapeutics Common Stock, respectively.
• The purchase price for the pre-funded warrants was $5.5099 per warrant.
• The pre-funded warrants are immediately exercisable and do not have an expiration date.
• However, a holder cannot exercise the warrants if it would result in them owning more than 9.99% of the outstanding Common Stock.
• Flagship Pioneering Special Opportunities Fund II General Partner LLC is the general partner of Flagship Pioneering Special Opportunities Fund II.
• Flagship Pioneering, Inc. is the manager of Flagship Pioneering Special Opportunities Fund II GP, and Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering.
• Flagship Pioneering Fund VII General Partner LLC is the general partner of Flagship Fund VII.
• Each reporting person disclaims beneficial ownership of the shares except to the extent of their pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports a transaction. There is no explicit positive or negative sentiment expressed, but the investment suggests a degree of confidence in the company's prospects.

Positives

• The acquisition of pre-funded warrants represents an investment in Foghorn Therapeutics by Flagship Pioneering funds.
• The warrants are immediately exercisable, providing potential for immediate conversion to common stock.
• The absence of an expiration date on the warrants provides flexibility for future exercise.

Risks

• The 9.99% ownership limit on warrant exercise could restrict the full potential benefit of the warrants if the holder already has a significant stake.
• The value of the warrants is dependent on the price of Foghorn Therapeutics' common stock, which is subject to market fluctuations.

Future Outlook

The document does not contain specific forward-looking statements regarding Foghorn Therapeutics' future performance, but the warrant acquisition suggests a continued interest in the company by Flagship Pioneering.

Industry Context

Form 4 filings are standard practice when significant transactions involving company stock occur with company insiders or major shareholders. This filing indicates Flagship Pioneering's continued investment in Foghorn Therapeutics, which is relevant in the context of the biotechnology industry and investment trends.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for insiders and large shareholders in publicly traded companies, ensuring transparency in the market.
• The acquisition of pre-funded warrants is a common investment strategy, particularly in the biotechnology sector, allowing investors to participate in potential future growth while managing risk.
• Similar transactions can be observed in other biotech companies with significant venture capital backing, such as Third Rock Ventures' investments in various portfolio companies.

Stakeholder Impact

• The acquisition of warrants could be viewed positively by shareholders as it signals continued investor confidence.
• The transaction has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates